Top 20 Companies in Global T-Cell Therapy Market (2024–2035): Competitive Analysis & Forecast
RELEASE DATE: Apr 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Introduction
The Global T-cell therapy Market encompasses advanced immunotherapies that utilize engineered T lymphocytes, such as CAR-T cells, to identify and destroy cancer cells with high specificity. These therapies represent a significant advancement in personalized medicine, particularly for hematological malignancies, and are increasingly being explored for solid tumors and autoimmune diseases. Market growth is driven by the rising global cancer burden, increasing demand for targeted therapies, and rapid advancements in gene editing and cell engineering technologies. Government and institutional data highlight strong momentum in this space; as of 2024, over 34,000 patients worldwide have received CAR-T therapies, reflecting growing clinical adoption. Additionally, more than 1,580 CAR-T clinical trials were registered globally by April 2024, indicating robust research activity. Expanding regulatory approvals, including multiple cell and gene therapy approvals in 2024, further support market expansion. Opportunities exist in developing allogeneic therapies, improving accessibility, and expanding indications beyond oncology. Recent developments include new approvals, safety monitoring requirements, and increased focus on scalable manufacturing to enhance global access. In November 2024, Roche announced the acquisition of Poseida Therapeutics in a deal worth up to $1.5 billion to expand its allogeneic CAR-T portfolio and in February 2024, AstraZeneca completed the acquisition of Gracell Biotechnologies to strengthen its cell therapy pipeline, particularly in CAR-T and autoimmune disease treatments. These developments indicate strong consolidation, increased investment, and continued product innovation, driving the T-cell therapy market forward
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global T cell therapy market.
Market Segmentation
Global T-Cell Therapy Market Size, Share, and, By Therapy Type (CAR-T Cell Therapy, TCR-T Cell Therapy, and Tumor-Infiltrating Lymphocyte (TIL) Therapy), By Indication (Hematological Malignancies, Solid Tumors, and Autoimmune Diseases), By Source (Autologous and Allogeneic), By End User (Hospitals, Cancer Treatment Centers, and Research Institutes), By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa), Analysis and Forecast 2024 – 2035.
Global T Cell Therapy Market Size & Statistics
- The Market Size for Global T Cell Therapy was estimated to be worth USD 5.21 Billion in 2024.
- The Market is going to expand at a CAGR of 12.09% between 2024 and 2035.
- The Global T Cell Therapy market size is anticipated to reach USD 18.29 Billion by 2035.
- North America is expected to generate the largest revenue during the forecast period in the Global T Cell Therapy market
- Asia Pacific is expected to grow at the fastest rate during the forecast period in the Global T Cell Therapy market.
Regional growth and demand
Asia Pacific is expected to grow at the fastest rate during the forecast period in the global T cell therapy market. Asia Pacific is expected to grow at the fastest rate due to expanding healthcare infrastructure, rising cancer incidence, and increasing government support for advanced therapies. Countries such as China and Japan are investing heavily in cell therapy research and clinical trials. The presence of a large patient pool, improving regulatory frameworks, and growing biopharmaceutical capabilities further accelerate regional market expansion.
North America is expected to generate the largest revenue during the forecast period in the global T cell therapy market. North America is expected to generate the highest revenue due to strong clinical adoption, advanced healthcare systems, and high investment in research and development. The United States leads due to early approvals of CAR-T therapies and the presence of major industry players. Supportive regulatory pathways and robust reimbursement structures continue to reinforce the region’s leading position.
Ready to lead the Global T-Cell Therapy Market?
Discover the regional trends and growth factors shaping the industry. We’re here to assist with expert, personalized data.
Call +1 303 800 4326 or Send us a message for a personalized consultation.
Top 10 Trends in the Global T-Cell Therapy Market
- Advancements In CAR-T Cell Therapy Technologies
- Growing Focus on Allogeneic (Off-The-Shelf) Therapies
- Expansion Into Solid Tumor Indications
- Integration Of Gene-Editing Technologies
- Increasing Strategic Collaborations and Partnerships
- Improvements In Manufacturing and Scalability
- Rising Regulatory Approvals and Supportive Frameworks
- Increasing Investment and Funding in Immunotherapy
- Development Of Combination Therapies
- Focus On Reducing Therapy Costs and Improving Accessibility
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global T cell therapy market.
- Advancements in CAR-T Cell Therapy Technologies
Continuous innovation in CAR-T cell therapy is significantly enhancing treatment outcomes and safety profiles. Next-generation CAR designs incorporate improved targeting mechanisms, dual-antigen recognition, and enhanced persistence of engineered T cells. These developments aim to overcome limitations such as relapse and antigen escape. Additionally, efforts to minimize adverse effects, including cytokine release syndrome and neurotoxicity, are strengthening clinical acceptance. The expansion of CAR-T therapies into earlier lines of treatment further supports their growing adoption. As clinical evidence continues to evolve, technological refinement remains a central driver shaping the future of T-cell therapy.
- Growing Focus on Allogeneic (Off-the-Shelf) Therapies
Allogeneic T-cell therapies are gaining traction as they offer significant advantages over autologous approaches, particularly in terms of scalability and cost efficiency. These therapies utilize donor-derived cells, enabling the production of standardized, ready-to-use treatments. This reduces manufacturing timelines and addresses logistical challenges associated with patient-specific therapies. Advances in gene editing are helping to mitigate risks such as graft-versus-host disease and immune rejection. As companies continue to invest in off-the-shelf platforms, allogeneic therapies are expected to expand access and transform the commercial viability of T-cell therapy globally.
- Expansion into Solid Tumor Indications
While T-cell therapies have demonstrated strong success in hematological malignancies, expanding their application to solid tumors represents a major area of focus. Researchers are developing innovative strategies to overcome challenges such as tumor microenvironment barriers, antigen heterogeneity, and limited T-cell infiltration. Approaches include engineering T cells with enhanced homing capabilities and resistance to immunosuppressive signals. Progress in this area could significantly broaden the addressable patient population. Ongoing clinical trials and pipeline developments indicate a growing commitment to unlocking the full potential of T-cell therapies in treating solid tumors.
- Integration of Gene-Editing Technologies
The incorporation of advanced gene-editing tools such as CRISPR-Cas9 is revolutionizing T-cell therapy development. These technologies enable precise modification of T cells to improve efficacy, persistence, and safety. Gene editing allows for the removal of inhibitory receptors, insertion of novel targeting elements, and creation of universal donor cells. This not only enhances therapeutic performance but also facilitates the development of allogeneic products. As research progresses, gene-editing integration is expected to accelerate innovation and expand the scope of applications within the T-cell therapy market.
- Increasing Strategic Collaborations and Partnerships
Strategic collaborations between biotechnology firms, pharmaceutical companies, and research institutions are becoming increasingly prevalent. These partnerships enable the sharing of expertise, resources, and technologies, accelerating product development and commercialization. Collaborative efforts often focus on clinical trials, manufacturing capabilities, and novel platform technologies. Such alliances also help mitigate risks and reduce development timelines in a highly complex and capital-intensive field. As competition intensifies, partnerships are expected to remain a key strategy for companies aiming to strengthen their market position and expand their therapeutic pipelines.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the global T cell therapy market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Top 20 Companies Leading the Global T-Cell Therapy Market
- Novartis AG
- Kite Pharma
- Bristol Myers Squibb
- Janssen
- Legend Biotech
- JW Therapeutics
- Autolus Therapeutics plc
- Allogene Therapeutics Inc.
- Adaptimmune Therapeutics plc
- CARsgen Therapeutics
- Cellectis S.A.
- Caribou Biosciences Inc.
- Lyell Immunopharma Inc.
- Cabaletta Bio Inc.
- Fate Therapeutics Inc.
- Atara Biotherapeutics Inc.
- Cartesian Therapeutics Inc.
- bluebird bio-Inc.
- Mustang Bio Inc.
- ImmunoACT
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global T cell therapy market.
- Novartis AG
Headquarters: Basel, Switzerland
Novartis AG, active in over 100 countries, is a leading player in the global T-cell therapy market, recognized for pioneering CAR-T therapy development. The company has established a strong commercial and clinical presence through its flagship therapy, Kymriah, targeting hematological malignancies. It focuses on advancing cell and gene therapies by strengthening manufacturing capabilities and expanding treatment accessibility worldwide. Novartis continues to invest in next-generation platforms and partnerships to enhance therapeutic outcomes. Its global footprint and early-mover advantage position it as a key contributor to the advancement and commercialization of T-cell therapies.
- Kite Pharma
Headquarters: Foster City, California, USA
Kite Pharma, a subsidiary of Gilead Sciences, active in over 35 countries, plays a significant role in the global T-cell therapy market. The company has built a strong portfolio of CAR-T therapies, including Yescarta and Tecartus, widely used in oncology treatment. Kite Pharma focuses on innovation in cell engineering and manufacturing efficiency to improve patient access. With a robust global treatment network and continued expansion into new indications, the company remains a major force in advancing T-cell therapies. Its integrated approach strengthens its position in the rapidly evolving immunotherapy landscape.
- Bristol Myers Squibb
Headquarters: New York City, New York, USA
Bristol Myers Squibb, active in more than 60 countries, is a prominent participant in the global T-cell therapy market with a focus on CAR-T innovations. The company offers therapies such as Breyanzi and Abecma, addressing various hematologic cancers. It emphasizes expanding clinical applications and enhancing manufacturing processes to support scalability. Through strategic collaborations and research initiatives, Bristol Myers Squibb continues to strengthen its cell therapy pipeline. Its global operational presence and commitment to innovation reinforce its role in driving growth and adoption of T-cell therapies across diverse healthcare systems.
- Janssen
Headquarters:
Janssen, a division of Johnson & Johnson, active in over 60 countries, maintains a strong presence in the global T-cell therapy market. The company is known for Carvykti, developed in collaboration with Legend Biotech, targeting multiple myeloma. It focuses on expanding therapeutic indications and improving patient outcomes through advanced cell therapy research. With a well-established global infrastructure and strong commercialization capabilities, Johnson & Johnson continues to enhance access to innovative treatments. Its strategic partnerships and research-driven approach support its growing influence in the T-cell therapy landscape.
- Legend Biotech
Headquarters: Nanjing, China
Legend Biotech, active in over 20 countries, is an emerging leader in the global T-cell therapy market, particularly in CAR-T development. The company gained recognition through its collaboration with Johnson & Johnson for the development of Carvykti. It focuses on advancing innovative cell therapies and expanding its pipeline across multiple cancer indications. Legend Biotech is strengthening its manufacturing and clinical capabilities to support global demand. Its expanding international footprint and strong research focus position it as a key contributor to the evolving T-cell therapy market.
Are you ready to discover more about the global T cell therapy market?
The report provides an in-depth analysis of the leading companies operating in the global T cell therapy market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Company Profiles
- Novartis AG
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Kite Pharma
- Bristol Myers Squibb
- Janssen
- Legend Biotech
- JW Therapeutics
- Autolus Therapeutics plc
- Allogene Therapeutics Inc.
- Adaptimmune Therapeutics plc
- Others.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Global T cell therapy market.
Conclusion
The global T-cell therapy market is witnessing significant growth, driven by the increasing prevalence of cancer, rising demand for personalized medicine, and continuous advancements in cell engineering technologies. T-cell therapies provide targeted and potentially curative treatment options, particularly for hematological malignancies, improving patient outcomes and survival rates. Innovations in gene editing, allogeneic platforms, and manufacturing processes further enhance scalability and accessibility. Leading companies such as Novartis AG, Kite Pharma Inc., Bristol Myers Squibb, Janssen and Legend Biotech are expanding their global presence, contributing to market development. Overall, T-cell therapies play a critical role in transforming modern oncology and advancing next-generation immunotherapy worldwide.
Our Industry Reports
PVC Window Market Size, Share, Forecasts to 2035
https://www.sphericalinsights.com/reports/pvc-window-market
Paracetamol Market Size, Forecast, Demand
https://www.sphericalinsights.com/reports/paracetamol-market
RNA Targeting Small Molecule Drug Discovery Market Size
https://www.sphericalinsights.com/reports/rna-targeting-small-molecule-drug-discovery-market
Germany Folic Acid Market Size, Forecast, Demand
https://www.sphericalinsights.com/reports/germany-folic-acid-market
Germany Humanoid Robot Market Size, Forecast, Demand
https://www.sphericalinsights.com/reports/germany-humanoid-robot-market
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI. Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?